Dear Pharmacy Team, I am writing to inform you that a patient will be dropping off a prescription for magic mouthwash today. The patient's name is John Doe, and he is experiencing severe mouth pain due to a recent oral surgery. After consulting with his dentist, it has been determined that magic mouthwash would be an appropriate treatment option for him. Please ensure that the prescription is processed promptly and provide the patient with clear instructions on how to use the medication. It is important that he understands the dosage and frequency of use, as well as any potential side effects or precautions. If there are any specific instructions or warnings that the patient should be aware of, please include them with the prescription.
A patient is dropping off a prescription for magic mouthwash
Two medicated mouthwashes led to reductions in oral mucositis pain for head and neck cancer patients treated with radiotherapy, but not at a level deemed clinically important, a randomized phase III study found. Within 4 hours of radiotherapy, pain from oral mucositis dropped by 11.7 points (as defined by the area under the curve) with a diphenhydramine-lidocaine-antacid rinse -- or "magic mouthwash" -- and 11.6 points with a doxepin mouthwash, compared with 8.7 points with placebo, reported Robert C. Miller, MD, MS, MBA, of the University of Maryland School of Medicine in Baltimore, and colleagues.
Over 80% of radiotherapy- and chemoradiotherapy-treated head and neck cancer patients develop the painful and debilitating complication, with severe symptoms requiring hospitalization and feeding tubes, they explained. Systemic analgesics and mouthwashes are frequently used to manage the condition. "For the diphenhydramine-lidocaine-antacid mouthwash, the current study provided the first evidence that the mouthwash appeared to be effective for short-term oral mucositis–related pain resulting from radiotherapy," Miller's group wrote in JAMA. "However, the mean differences in pain reduction by the area under the curve for both treatment intervention mouthwashes were less than the minimal clinically important difference of 3.5 points." Compared with placebo, diphenhydramine-lidocaine-antacid led to a 3.0-point improvement (95% CI 0.1-5.9, P=0.004) while the doxepin mouthwash led to a 2.9-point improvement (95% CI 0.2-6.0, P=0.02). "These data tell us that magic mouthwash (or doxepin) is not the sole answer to managing mucositis -- physicians should not prescribe magic mouthwash and expect magic!" Arjun Gupta, MD, of the Sidney Kimmel Comprehensive Cancer Center in Baltimore, told MedPage Today in an email. "We have very few drugs to treat [these] patients in great suffering, and we need more drugs in well-designed trials to urgently address this question."
Gupta, who was not involved in the research, previously co-authored a perspective calling into question the routine use of magic mouthwash for oral mucositis, with issues ranging from the limited efficacy, potential for high out-of-pocket costs, among other concerns. "In the real world, there is no fixed formula for magic mouthwash. Most providers do not know the contents or concentrations of the ingredients in these mixed-medication formulations," he said. "They could also contain unnecessary and harmful ingredients such as steroids and antibacterials/antifungals. How many other drugs do physicians prescribe without knowing the contents or concentration?"
"Steroids, especially in a patient with dry mouth, may induce local secondary fungal infections that exacerbate oral pain," said Sharon Elad, DMD, MSc, of the University of Rochester Medical Center in New York, and Noam Yarom, DMD, of Tel Aviv University in Israel, in an editorial that accompanied the study. "Furthermore, the use of a single term for multiple compounds hampers clear communication between professionals, and, ideally, the term should be uniform and describe the actual active ingredients."
For this reason, said Gupta, the American Academy of Nursing recommends against use of mixed-medication mouthwash for managing oral mucositis. Gupta also noted that previous research has shown similar efficacy between a magic mouthwash similar to that used in this Alliance study, chlorhexidine, and a salt and soda mix. "Given the ease of preparation at home and almost no cost (1 teaspoon of salt and sodium bicarbonate each in 1 liter of water), salt and soda mouthwash is often prescribed by physicians," he said, adding that had this been used in place of the placebo, or as a fourth study arm, it might have demonstrated equivalence or superiority over the investigational agents. Drowsiness, stinging or burning, and unpleasant taste were examined as secondary outcomes on scales ranging from best to worst (0-10). With the doxepin rinse compared with placebo: drowsiness (1.5 points higher, P=0.03) and unpleasant taste (1.5 points higher, P=0.002) were worse than placebo. No significant differences were seen between the diphenhydramine-lidocaine-antacid and placebo groups.
- Doxepin: 79.5%, P=0.14
- Diphenhydramine-lidocaine-antacid: 85.5%, P=0.02
"This suggests that a subgroup of patients may have experienced meaningful benefits from the diphenhydramine-lidocaine-antacid mouthwash," the editorialists wrote.
For the Alliance A221304 study, Miller's team randomized 275 patients (1:1:1) at 30 institutions in the U.S. from 2014 to 2016. All patients had a minimum pain score of 4 (out of 10). In all, 92 patients received the 25-mg doxepin mouthwash (in a 5-mL solution), 92 received a 5-mL placebo mouthwash consisting of water and Ora-Sweet SF (2.5 mL each), and 91 received a 5-mL solution of 12.5 mg diphenhydramine, 2% lidocaine, and an antacid (200 mg of aluminum hydroxide, 200 mg of magnesium hydroxide, and 20 mg of simethicone).
Limitations of the study included the fact that it was only designed to assess pain at up to 4 hours after administration of the mouthwash, while post-radiotherapy pain can persist for days.
This study was funded by the Alliance for Clinical Trials, the National Cancer Institute, and the Mayo Clinic Symptom Intervention Program.
Miller reported non-financial support from CutisPharma.
Elad reported relationships with Falk Pharma, the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer, and the International Society of Oral Oncology.
Gupta reported no disclosures.
Source Reference: Sio TT, et al "Effect of doxepin mouthwash or diphenhydramine-lidocaine-antacid mouthwash vs placebo on radiotherapy-related oral mucositis pain: The Alliance A221304 randomized clinical trial" JAMA 2019; 321(15): 1481-1490.
Source Reference: Elad S, Yarom N "The search for an effective therapy and pain relief for oral mucositis" JAMA 2019; 321(15): 1459-1461.
Beyond-use dating of lidocaine alone and in two "magic mouthwash" preparations
Purpose: Beyond-use dating (BUD) of lidocaine alone and in two "magic mouthwash" preparations stored in amber oral syringes at room temperature was determined.
Methods: Two formulations of mouthwash containing oral topical lidocaine 2% (viscous), diphenhydramine 2.5 mg/mL, and aluminum hydroxide-magnesium hydroxide-simethicone were prepared in 1:1:1 and 1:2.5:2.5 ratios, divided into 3-mL samples, and stored in unit-dose oral amber syringes. Unit-dose single-product lidocaine samples were also prepared to serve as controls and stored in oral amber syringes. The lidocaine concentrations in these samples were measured periodically for 90 days. A stability-indicating high-performance liquid chromatographic method was developed and validated for system suitability, accuracy, repeatability, intermediate precision, specificity, linearity, and robustness.
Results: Based on the calculated percentages versus the initial concentration and the results from an analysis of variance comparing the two formulations, a BUD of 21 days is deemed appropriate for both magic mouthwash formulations. Based on the stability data, published safety concerns, and lack of efficacy in combination, packaging and dispensing lidocaine separately from other ingredients are recommended when administering magic mouthwash mixtures. Utilizing a 90-day BUD, lidocaine can be packaged separately from other magic mouthwash ingredients in individual dosage units and applied to the oral cavity using the swish-and-spit method. The delivery of the diphenhydramine and aluminum hydroxide-magnesium hydroxide-simethicone could be separated, allowing for a swish-and-swallow method of administration.
Conclusion: A BUD of 21 days is recommended for lidocaine prepared with diphenhydramine and aluminum hydroxide-magnesium hydroxide-simethicone in ratios of 1:1:1 and 1:2.5:2.5 and stored at room temperature in amber oral plastic syringes.
Keywords: chromatography; drug stability; high pressure liquid; lidocaine; magic mouthwash; mucositis.
Copyright © 2017 by the American Society of Health-System Pharmacists, Inc. All rights reserved.
If there are any specific instructions or warnings that the patient should be aware of, please include them with the prescription. Additionally, please check the patient's insurance coverage for magic mouthwash to determine if it is covered, and inform the patient of any associated costs. If the cost is a concern for the patient, we recommend discussing alternative options with the prescribing dentist.
Similar articles
Chan A, Ignoffo RJ. Chan A, et al. J Oncol Pharm Pract. 2005 Dec;11(4):139-43. doi: 10.1191/1078155205jp166oa. J Oncol Pharm Pract. 2005. PMID: 16595065
Dodd MJ, Dibble SL, Miaskowski C, MacPhail L, Greenspan D, Paul SM, Shiba G, Larson P. Dodd MJ, et al. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Jul;90(1):39-47. doi: 10.1067/moe.2000.105713. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000. PMID: 10884634 Clinical Trial.
Sio TT, Le-Rademacher JG, Leenstra JL, Loprinzi CL, Rine G, Curtis A, Singh AK, Martenson JA Jr, Novotny PJ, Tan AD, Qin R, Ko SJ, Reiter PL, Miller RC. Sio TT, et al. JAMA. 2019 Apr 16;321(15):1481-1490. doi: 10.1001/jama.2019.3504. JAMA. 2019. PMID: 30990550 Free PMC article. Clinical Trial.
Faden H. Faden H. Pediatr Emerg Care. 2006 Apr;22(4):268-9. doi: 10.1097/01.pec.0000218982.46225.f5. Pediatr Emerg Care. 2006. PMID: 16651921 Review.
Worthington HV, Clarkson JE, Eden OB. Worthington HV, et al. Cochrane Database Syst Rev. 2002;(1):CD001973. doi: 10.1002/14651858.CD001973. Cochrane Database Syst Rev. 2002. PMID: 11869616 Updated. Review.
Finally, please ensure that the prescription label is clear and easy to read. This includes including the patient's name, the medication name (magic mouthwash), dosage instructions, and any necessary warnings or precautions. It is essential that the label is accurate and that the patient can understand the information provided. Thank you for your attention to this matter. If you have any questions or need further information, please do not hesitate to contact me. Sincerely, [Your Name] [Your Title/Role].
Reviews for "Magic Mouthwash vs. Traditional Oral Medications: Which is Better?"
1. Brenda - 1 star
I was very disappointed with "A patient is dropping off a prescription for magic mouthwash". I found the storyline to be extremely dull and uninteresting. It lacked depth and failed to hold my attention. The characters were poorly developed, making it difficult to connect or sympathize with them. The writing style was also very mediocre and lacked creativity. Overall, I felt like I wasted my time reading this book and would not recommend it to others.
2. David - 2 stars
"A patient is dropping off a prescription for magic mouthwash" was an underwhelming read for me. While the concept of magically healing mouthwash was intriguing, the execution fell flat. The pacing was uneven, with long periods of nothing happening followed by rushed and unclear resolutions. The main characters lacked depth and often made decisions that defied logic. The dialogue felt forced and unnatural, making it difficult to engage with the story. I had high hopes for this book, but unfortunately, it failed to deliver an enjoyable reading experience.